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Abstract The Rad51 gene of Saccharomyces cerevisiae is
required for genetic recombination and recombinational repair
of DNA strand breaks. In higher eukaryotes Rad51 is essential
for embryonic development, and is involved in cell proliferation
and DNA repair. Here we show that human Rad51 (HsRad51) is
proteolytically cleaved during apoptosis in two T-lymphocyte cell
lines, Jurkat and PFI-285. Apoptosis was induced by camptothe-
cin or anti-Fas monoclonal antibody (anti-Fas mAb). HsRad51
was cleaved with similar kinetics as human poly(ADP-ribose)
polymerase (HsPARP) after treatment with either agent. The
time course of cleavage coincided with internucleosomal DNA
fragmentation. The HsRad51 fragments observed in apoptotic
cells were identical to those generated from in vitro translated
(IVT) HsRad51 exposed to activated Jurkat S-100 extract in a
cell-free system. In each case, cleavage of HsRad51 was
abolished by acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-
CHO). However, cleavage of IVT HsRad51 could not be
demonstrated using purified caspase-2, -3 or -6 to -10, and the
identity of the responsible protease thus remains to be
determined. In summary, we have shown that HsRad51 belongs
to a group of repair proteins, including PARP and DNA-
dependent protein kinase, which are specifically cleaved during
the execution phase of apoptosis.
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1. Introduction
Apoptosis is a distinct form of programmed cell death
mediated by di¡erent stimuli, including DNA damaging
agents and Fas/Fas ligand interaction [1]. It is characterized
by several features, two of these being plasma membrane
blebbing and internucleosomal degradation of chromosomal
DNA. Speci¢c cysteine proteases of the interleukin-1L-con-
verting enzyme (ICE) family initiate the execution stage of
apoptosis [2]. These proteases, commonly called caspases [3],
recognize a sequence of ¢ve amino acids: P4^P1 followed by
PP, and speci¢cally cleave substrates C-terminal to an aspartic
acid residue at the P1 site [4]. The cleavage can lead to acti-
vation or inactivation of substrates, which include cytoskeletal
components and proteins involved in signal transduction,
RNA processing and DNA repair [5,6]. Many of these pro-
teins are likely to be involved in the morphological and bio-
chemical changes that accompany apoptosis, although the ex-
act functional roles of the cleavages are not clear. Recently the
involvement of a caspase in the activation of the DNase ac-
tivity causing DNA fragmentation in nuclei has been observed
[7,8]. Poly(ADP-ribose) polymerase (PARP) and the catalytic
subunit of the DNA-dependent protein kinase (DNA-PKcs),
both involved in DNA damage sensing and repair [9,10], are
inactivated by caspase cleavage [11^16]. The signi¢cance of
PARP cleavage is indicated by a recent study showing that
PARP knock-out mice display enhanced susceptibility to
DNA fragmentation [17]. Further identi¢cation of the targets
of the caspases is important for the understanding of the
apoptotic process.
Like PARP and DNA-dependent protein kinase (DNA-
PK), the Rad51 protein binds to DNA and plays a role in
repair. Saccharomyces cerevisiae Rad51 is involved in recom-
bination and repair of DNA strand breaks [18,19]. Mutations
in the gene sensitize yeast cells to ionizing radiation and abol-
ish recombination [18,19]. Overall homology between the hu-
man Rad51 (HsRad51) and S. cerevisiae Rad51 proteins is
68% [20,21], and both proteins catalyze ATP- dependent
DNA strand exchange reactions in vitro [22^25]. Recently a
direct role for HsRad51 in recombination in human immor-
talized cells was suggested [26]. Several reports have indicated
an involvement of mammalian Rad51 in repair; nuclear foci
of Rad51 protein are formed in human ¢broblasts after DNA
damage [27], antisense inhibition of mouse Rad51 enhances
radiosensitivity [28] and Rad51 homozygous mutant mouse
embryos are hypersensitive to ionizing radiation [29]. Mam-
malian Rad51 may also have an essential role in replication,
since targeted disruption of the murine Rad51 gene leads to
embryonic lethality [30], and depletion of Rad51 in chicken B
lymphocytes is accompanied by chromosome aberrations and
cell death [31].
Here we demonstrate that HsRad51, like PARP and DNA-
PKcs, is proteolytically cleaved during apoptosis in two T-cell
lines and in vitro. The cleavage is Ac-DEVD-CHO inhibit-
able, but the caspase/protease directly responsible for the
cleavage remains to be determined.
2. Materials and methods
2.1. Cells and culture conditions
PFI-285, a transformed T-lymphocyte cell line with a nearly normal
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karyotype [32], kindly provided by Dr. Anne-Lise BÖrresen, Norsk
Radium Hospital, Oslo, was cultured as previously described [32].
Jurkat, a T-lymphocyte cell line, was cultured in nutrient medium
(NM), which is RPMI 1640 purchased from Gibco (USA) containing
10% newborn calf serum, 10 Wg/ml streptomycin, 150 IU/ml benzyl-
penicillin and 20 mM L-glutamine.
2.2. Reagents
Tosyl-L-phenylalanine chloromethyl ketone (TPCK) was purchased
from Calbiochem (USA), acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-
DEVD-CHO) and acetyl-Tyr-Val-Ala-Asp-aldehyde (Ac-YVAD-
CHO) from Neosystem Laboratoire (France). Camptothecin, phenyl-
methylsulfonyl £uoride (PMSF), leupeptin, aprotinin, pepstatin and
dithiothreitol (DTT) were obtained from Sigma (USA) and anti-hu-
man Fas monoclonal antibody (IgM CH-11 clone) from Medical and
Biological Laboratories, Nagoya (Japan). Cytochrome c was obtained
from Calbiochem, and dATP from Pharmacia (Sweden).
2.3. Western blotting
Western blotting was performed as previously described [33]. 50 Wg
of protein per lane was resolved by 12% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE).
2.4. Primary antibodies
HsRad51 polyclonal antibody was prepared as described previously
[33]. PARP monoclonal antibody C-2-10 was generously provided by
Dr. Guy Poirier, Centre Hospitalier de L’UniversiteŁ Laval, Canada.
2.5. Internucleosomal DNA fragmentation
Cells (1U106) were collected by centrifugation at 1000Ug for 5 min.
Pellets were resuspended in 300 Wl cold lysis bu¡er (5 mM Tris, 20 mM
EDTA, 0.5% Triton X-100, pH 8.0) and 300 Wl polyethylene glycol
(PEG) solution (5% PEG, 2 M NaCl). Samples were left on ice for
10 min, and supernatants were cleared by centrifugation at 12 000Ug
for 10 min. 1 ml ice-cold 99% ethanol and 30 Wl 5 M NaCl was added
to the supernatants. Samples were stored at 320‡C overnight, and
centrifuged at 12 000Ug for 15 min the following day. Pellets were
lyophilized and dissolved in 10 Wl 1UTE bu¡er (10 mM Tris, 1 mM
EDTA, pH 8.0). 10 Wl RNase stock (500 U/ml RNase T1, 5 mg/ml
RNase A) was added, and samples were incubated for 1 h at 37‡C. 2 Wl
proteinase K (25 mg/ml) was added, followed by incubation for 1 h at
37‡C. 8 Wl loading bu¡er (356 mM Tris, 356 mM boric acid, 0.8 mM
EDTA, 40% sucrose, 0.05% bromophenol blue, 0.5% SDS) was
added, and DNA fragments were separated on an 1.8% agarose gel
in 0.5UTBE bu¡er (44.5 mM Tris, 44.5 mM boric acid, 0.1 mM
EDTA). The gel was stained for 30 min in 0.5 Wg/Wl ethidium bro-
mide. DNA was visualized with UV (305 nm) light.
2.6. Generation and activation of Jurkat S-100 extracts
Human Jurkat cells were grown as described [34]. The cells (2 liters
at 0.8U106/ml) were harvested by centrifugation. After one wash in
ice-cold PBS the cells were resuspended in ice-cold bu¡er A (20 mM
HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 0.1 mM PMSF, 5 Wg/ml pepstatin A, 10 Wg/ml
leupeptin, and 2 Wg/ml aprotinin). After incubation on ice for 15 min,
the cells were lysed by douncing 20 times in a 7 ml Kontes douncer
with the B pestle. Nuclei were centrifuged at 1000Ug for 10 min at
4‡C. The supernatant was centrifuged further at 100 000Ug yielding
Jurkat S-100. Activation was achieved by incubating 100 WM dATP
and 0.2 Wg cytochrome c for every 25 Wg S-100 in 20 Wl at 30‡C for 1 h.
The resulting activated S-100 was tested for acetyl-Asp-Glu-Val-Asp-
aminomethylcoumarin (Ac-DEVD-AMC) cleaving activity prior to
use with in vitro translated substrates. Ac-DEVD-AMC was synthe-
sized as described [34].
2.7. Cleavage of in vitro translated HsRad51 and HsPARP
35S-radiolabelled, in vitro translated (IVT) HsRad51 or HsPARP
was generated using a TNT-linked transcription/translation kit
(Promega, Madison, WI) according to the manufacturer’s instruc-
tions. Brie£y, human Rad51 cDNA in pGEM5Z from Promega
(USA) or human PARP cDNA in pBluescript from Stratagene
(USA) were incubated with T7 polymerase, 40 WCi of [35S]methionine,
and TNT kit components. IVT HsRad51 or IVT HsPARP (2% of
total TNT reaction) were incubated with activated Jurkat S-100 ex-
tract for 5 h at 30‡C. Reactions were boiled in Laemmli bu¡er, re-
solved by either 14% or 10% SDS-PAGE, and the protein bands were
visualized with a phosphoimager.
3. Results
In contrast to the induction of Rad51 expression by DNA
damaging agents in yeast [35^37], no increase in HsRad51
protein levels could be detected in human peripheral blood
lymphocytes after treatment with DNA damaging agents. In-
stead, a decrease in the HsRad51 protein level was observed
after treatment with high doses of ionizing irradiation, methyl
methanesulfonate or nitrogen mustard (data not shown). To
examine a possible connection between the decrease of
HsRad51 expression and apoptosis, further studies were car-
ried out in Jurkat cells. Apoptosis was induced by treatment
with the topoisomerase I inhibitor camptothecin or anti-Fas
mAb. Cell extracts were prepared at indicated time points,
and analyzed by Western blotting (Fig. 1A). The full-length
HsRad51 has a predicted molecular weight of 37 kDa, but
migrates at 41 kDa. In Jurkat cells treated with 13 WM camp-
tothecin, a 33 kDa band appeared 3 h after treatment. Similar
kinetics were observed for cleavage of the 116 kDa HsPARP
protein into a 89 kDa product (Fig. 1A). The same pattern
was seen in Jurkat cells treated with 37 ng/ml anti-Fas mAb
(Fig. 1B). The time course of cleavage coincided with inter-
nucleosomal DNA fragmentation (Fig. 1C,D). This suggests
that the 33 kDa fragment is an apoptosis-related cleavage
product of HsRad51.
To con¢rm this conclusion, a cell-free system was used. IVT
HsRad51 or HsPARP were added to activated Jurkat S-100
extract. The samples were incubated at 30‡C for 5 h and
resolved by 14% SDS-PAGE. A HsRad51 cleavage product
of 33 kDa, similar in size to the 33 kDa fragment in Jurkat
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Fig. 1. Cleavage of HsRad51 and HsPARP in relation to DNA
fragmentation in Jurkat cells. Western blot analysis of HsRad51
and HsPARP expression up to 5 h after treatment with (A) 13 WM
camptothecin or (B) 37 ng/ml anti-Fas mAb. The membrane previ-
ously probed with HsRad51 antibody was stripped and re-probed
with HsPARP antibody. Internucleosomal DNA fragmentation in
Jurkat cells up to 5 h after treatment with (C) 13 WM camptothecin
or (D) 37 ng/ml anti-Fas mAb.
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cells, was observed (Fig. 2A). Cleavage of IVT HsPARP to
generate an 89 kDa fragment was also observed under the
same conditions (Fig. 2B). These results con¢rm that the 33
kDa band previously observed by immunoblotting is indeed
derived from the HsRad51 protein, and not caused by cross-
reaction of the antibody with another protein.
Studies with inhibitors were performed in two T-cell lines to
assess which group of proteases was responsible for the ob-
served HsRad51 cleavage. PFI-285 cells were pre-treated with
the inhibitors for 15 min followed by exposure to 13 WM
camptothecin. Cells were harvested 5 h after treatment, and
proteins were analyzed by Western blotting (Fig. 3A). 200 WM
of TPCK, an inhibitor of serine proteases [38], completely
abrogated the cleavage (lane 3) observed in the sample treated
with camptothecin without inhibitor (lane 2). 100 WM of the
caspase-1-like protease inhibitor Ac-YVAD-CHO [11] did not
signi¢cantly inhibit the cleavage (lane 4), while an equimolar
concentration of the broader caspase-3-like inhibitor Ac-
DEVD-CHO [11] completely abolished the cleavage (lane 5).
The inhibition study was repeated in Jurkat cells using the
same concentration of TPCK, but ¢ve times lower concentra-
tions of the caspase inhibitors. Pre-treatment with 200 WM
TPCK or 20 WM Ac-YVAD-CHO did not have any e¡ect,
while 20 WM Ac-DEVD-CHO signi¢cantly inhibited the cleav-
age (Fig. 3B). Thus, the inhibition of HsRad51 cleavage by
TPCK or Ac-DEVD-CHO was reproducible in two di¡erent
T-cell lines.
The inhibition of HsRad51 cleavage by Ac-DEVD-CHO
was con¢rmed in the cell-free assay described above. Ac-
DEVD-CHO (200 nM) was added to the activated S-100
cell extract prior to the addition of IVT HsRad51. Cleavage
of IVT HsRad51 was completely inhibited by Ac-DEVD-
CHO (Fig. 4A). Inhibition of cleavage of HsPARP under
the same conditions was also observed (Fig. 4B). Sensitivity
to this concentration of the inhibitor suggests the involvement
of a caspase-3- rather than caspase-1-like protease in
HsRad51 cleavage. This ¢nding is consistent with the above
in vivo data.
An attempt was made to determine which caspase was re-
sponsible for the cleavage. IVT HsRad51 was exposed to re-
combinant, puri¢ed caspase-2, -3, -6, -7, -8, -9 or -10 for 1 h at
30‡C. While HsPARP, which was used as a control, was
cleaved by the caspases, no cleavage of HsRad51 was ob-
served (data not shown).
4. Discussion
We have observed proteolytic cleavage of HsRad51 protein
in Jurkat and PFI-285 cells treated with camptothecin or anti-
Fas mAb. The cleavage coincided with internucleosomal
DNA fragmentation, which indicates an association with
apoptosis. HsRad51 was cleaved with similar kinetics to
PARP, a protein implicated in the detection of DNA strand
breaks [10]. Part of the HsRad51 protein in the cells and in
the in vitro system remained uncleaved. This might be ex-
plained by the spatial distribution of the protein [27,39], or
by interactions between HsRad51 and other proteins [40^47],
which may protect the cleavage site.
Pre-incubation with the serine protease inhibitor TPCK ab-
rogated the cleavage in cells treated with 13 WM camptothe-
cin. This indicates that serine proteases may be involved in the
apoptotic pathway leading to HsRad51 cleavage, an interpre-
tation supported by a recent demonstration of a TPCK-sensi-
tive step in the activation of caspase-3 [48]. On the other
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Fig. 3. Western blot analysis of HsRad51 in Jurkat and PFI-285
cells treated with camptothecin and protease inhibitors. A: PFI-285
cells treated with 1.0 WM camptothecin for 5 h. Lane 1, untreated
control; lanes 2^5, camptothecin-treated cells preincubated for
15 min with: lane 2, no inhibitor; lane 3, 200 WM TPCK; lane 4,
100 WM Ac-YVAD-CHO; lane 5, 100 WM Ac-DEVD-CHO. B: Jur-
kat cells treated with 13 WM camptothecin for 5 h. Lane 1, un-
treated control; lanes 2^5, camptothecin-treated cells preincubated
for 15 min with: lane 2, no inhibitor; lane 3, 200 WM TPCK; lane
4, 20 WM Ac-YVAD-CHO; lane 5, 20 WM Ac-DEVD-CHO.
Fig. 4. Inhibition of cleavage of in vitro translated 35S-radiolabelled
HsRad51 and HsPARP. IVT HsRad51 (A) or IVT HsPARP (B)
was incubated with: lane 1, control S-100 extract; lane 2, S-100 ex-
tract which had been activated by cytochrome c and dATP; lane 3,
activated S-100 to which 200 nM Ac-DEVD-CHO was added just
prior to incubation with IVT products. Following incubation for
5 h, samples were resolved by (A) 14% or (B) 10% SDS-PAGE. Ar-
rows indicate cleavage products in lanes A2 and B2.
Fig. 2. Cleavage of in vitro translated 35S-radiolabelled HsRad51
and HsPARP by apoptotic Jurkat S-100 extract. IVT HsRad51 (A)
or IVT HsPARP (B) was incubated with: lane 1, control S-100 ex-
tract; lane 2, S-100 extract which had been activated by cytochrome
c and dATP. Following incubation for 5 h, samples were resolved
by (A) 14% or (B) 10% SDS-PAGE. Arrows indicate cleavage prod-
ucts in lanes A2 and B2.
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hand, 200 WM TPCK has been shown to induce necrosis in
Jurkat cells and abolish the features of apoptosis [49]. There-
fore, we cannot rule out the possibility that the inhibitory
e¡ect of TPCK on HsRad51 cleavage may be due to induc-
tion of necrosis instead of apoptosis.
Ac-YVAD-CHO, an e¡ective inhibitor of proteases with
the highest homology to caspase-1 [50], did not signi¢cantly
inhibit the cleavage of HsRad51 in cells. Ac-DEVD-CHO,
originally designed as an inhibitor of caspase-3 [11], abolished
the cleavage of HsRad51 in cells and in vitro. In an earlier
study 50 WM Ac-DEVD-CHO did not substantially prevent
anti-Fas mAb induced cell death and DNA laddering in Jur-
kat cells [49]. Thus, the observed inhibitory e¡ect of 20 WM
Ac-DEVD-CHO on HsRad51 cleavage in Jurkat cells is not
likely to be caused by an abrogation of apoptosis. However,
neither puri¢ed caspase-3 nor caspase-2, -6, -7, -8, -9 or -10
was able to cleave IVT HsRad51. Thus HsRad51 cleavage is
sensitive to Ac-DEVD-CHO inhibition, but not executed di-
rectly by a known Ac-DEVD-CHO-inhibitable caspase such
as caspase-7 or -3. One explanation for this observation could
be that an Ac-DEVD-CHO inhibitable caspase activates a
downstream protease for HsRad51 cleavage. Alternatively
an Ac-DEVD-CHO inhibitable caspase other than the ones
tested could be directly responsible for HsRad51 cleavage.
Multiple active forms of unidenti¢ed caspases have been dis-
covered in HL-60 cells following induction of apoptosis with
etoposide [51]. Thus it is possible that HsRad51 is cleaved by
either a caspase which is unknown to date or by a non-cas-
pase protease.
There is no DEVD site in the HsRad51 amino acid se-
quence that would generate a 33 kDa fragment following
cleavage. However, DEVD-based compounds are broad in-
hibitors which cannot be assumed to selectively inhibit cas-
pase-3 [6], especially when used at high concentrations [50].
Thus an Ac-DEVD-CHO inhibitable caspase could act di-
rectly on one of a few putative HsRad51 cleavage sites con-
taining a P1 Asp and an amino acid other than Asp in the P4
position, e.g. AQVD-G, amino acids 271^275. Cleavage here
would give a product of approximately 30 kDa. In vitro muta-
genesis of the putative cleavage sites in the HsRad51 protein
may help to elucidate the involvement of speci¢c caspases.
What is the functional importance of the HsRad51 cleav-
age? Rad51 is involved in recombinational repair of DNA
strand breaks in yeast [18,19], and several recent reports in-
dicate that the Rad51 homologues in higher eukaryotes may
have a similar role [26^28,52,53]. An association with DNA
replication is suggested by increased Rad51 expression during
S/G2 phase [33], and formation of Rad51 positive nuclear foci
during the S phase in mammalian cells [39]. In S. cerevisiae,
repair using intrachromosomal recombination between sister
chromatids in G2 is preferred to interchromosomal recombi-
nation between homologous chromatids [54]. Similarly, inter-
chromosomal recombination is suppressed in human cells [55].
It is tempting to speculate that HsRad51 might exert func-
tions in the repair of DNA strand breaks by catalyzing intra-
chromosomal recombination between sister chromatids during
the S/G2 phase. Such an activity might obstruct the apoptotic
process, and this could be prevented by inactivating HsRad51.
Since HsRad51 is essential for cell survival, cleavage of the
protein may also be of importance for the irreversibility of
apoptosis [29,30].
In conclusion, we have shown that HsRad51, like PARP
and DNA-PKcs, is cleaved during the execution phase of
apoptosis. The cleavage is Ac-DEVD-CHO inhibitable, but
the protease responsible for the cleavage remains to be deter-
mined.
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